Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028519 · ClinicalTrials.gov registry record · Early Phase 1
Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer
A Early Phase 1 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 81
- Enrollment target
NCT03028519 is a Early Phase 1 study that has completed, run by University of Oklahoma. The registered enrollment target is 81 participants.
The verdict
NCT03028519, a Early Phase 1 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
This study will evaluate serum vitamin D (25(OH)D) and serum leptin levels at the time of diagnosis of ovarian, primary peritoneal, and/or fallopian tube cancer as well as vitamin D receptor mutation status (FokI SNP genotype). The study will evaluate the impact of vitamin D repletion on serum vitamin D levels, serum leptin levels, and treatment-related morbidity in these patients.
Interventions
- DRUG Vitamin D3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2017-01-31 |
| Est. Completion | 2020-12-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03028519
The ClinicalTrials.gov registry entry for NCT03028519 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vitamin D3 is the first listed.
NCT03028519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03028519 about?
NCT03028519 is a clinical study titled "Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer". This study will evaluate serum vitamin D (25(OH)D) and serum leptin levels at the time of diagnosis of ovarian, primary peritoneal, and/or fallopian tube cancer as well as vitamin D receptor mutation status (FokI SNP genotype). The study will evaluate the impact of vitamin D repletion on serum vitam...
What is the current status of trial NCT03028519?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 81 participants. The study started on 2017-01-31. Estimated completion is 2020-12-30.
What interventions are being tested in trial NCT03028519?
The interventions under investigation include: Vitamin D3 (DRUG).
Who is sponsoring clinical trial NCT03028519?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.